ClinicalTrials.gg
CompletedNCT04049760Updated Feb 5, 2026Results posted

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 6 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
12th of 20
16 · median 20
Started
2019
the only one that year
Phase 3
11 of 20
2 open now
Registered
18th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 3, and was the 18th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Lysosomal disease
  • migalastat
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects diagnosed with Fabry disease > 12 years of age who completed Study AT1001-020
  • Subject's parent or legally-authorized representative is willing and able to provide written and authorization for use and disclosure of personal health information or research-related health information, and subject provides assent, if applicable
  • If of , both male and female subjects agreed to use a medically accepted method of throughout the duration of the study and for up to 30 days after their last dose of migalastat

Exclusion criteria

Exclusion Criteria:

  • Subject's last available estimated (eGFR) in the previous study was \< 60 mL/min/1.73 m2
  • Subject had advanced kidney disease requiring dialysis or kidney transplantation
  • Subject received any /experimental drug, biologic, or device within 30 days before baseline, with the exception of migalastat
  • Subject anticipated starting gene therapy during the study period
  • Subject had any intercurrent illness or condition at Visit 1 that may have precluded the subject from fulfilling the protocol requirements or suggested to the investigator that the potential subject may have an unacceptable risk by participating in this study
  • Subject had a history of allergy or sensitivity to migalastat (including ) or other iminosugars (eg, miglustat, miglitol)
  • Subject required treatment with Replagal® (agalsidase alfa) or Fabrazyme® (agalsidase beta)
  • Subject required treatment with Glyset® (miglitol) or Zavesca® (miglustat)
  • Female subject was pregnant or breast-feeding, or was planning to become pregnant during the study period
  • In the opinion of the investigator, the subject and/or parent or legally-authorized representative was unlikely or unable to comply with the study requirements
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    migalastat HCl 150 mg

    One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.

    Drug: migalastat HCl 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug

    Number of subjects with TEAE, SAE, and AE leading to discontinuation during the study period

    Time frame: Entire study

Secondary outcomes

  1. Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)

    Estimated GFR was calculated using the modified Schwartz formula according to the standards of the central laboratory.

    Time frame: Baseline, Month 24

  2. Change From Baseline to Month 24 in Urine Protein Levels

    Renal function was assessed by urine protein levels (mg/L). Urine samples were collected as part of urinalysis.

    Time frame: Baseline, Month 24

  3. Change From Baseline to Month 24 in Urine Albumin

    Renal function was assessed by urine albumin levels (mg/L). Urine samples were collected as part of urinalysis

    Time frame: Baseline, Month 24

  4. Change From Baseline to Month 24 in Left Ventricular Mass Index (LVMi)

    LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M-mode and 2D views are presented.

    Time frame: Baseline, Month 24

  5. Change From Baseline to Month 24 in Pediatric and Quality of Life Inventory™ (PedsQL™) Scores

    The Pediatric Quality of Life Inventory (PedsQL™) was a modular approach to measuring health-related quality of life (QoL) in healthy children and adolescents and those with acute and chronic health conditions. All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Psychosocial, physical, and total scores were calculated based on the response to the questions within the patient reported outcome. The psychosocial score for the PedsQL encompassed 15 questions relating to the subjects' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the subjects' ease of managing physical activity. Total scores were the sum of all the item scores over the number of items answered on all the scales. Change from baseline values of \<0 represents worsening, 0 equals no change, and \>0 represents improvement.

    Time frame: Baseline, Month 24

  6. Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity

    The Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) included questions about Fabry disease-specific symptoms. The assessment of "How bad is your pain today?" was measured on a 10- point scale from 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.

    Time frame: Baseline, Month 24

  7. Number of Subjects Who Experienced Sudden Onset of Pain As Assessed Using the Fabry-Specific Health and Pain Questionnaire (FPHPQ)

    Subjects were asked "In the last 3 months how many times did you experience sudden onset of pain?" and responses were reported in the FPHPQ. Responses were categorized as 0, 1 to 3, 4 to 6, and \> 6 occurrences of sudden onset of pain.

    Time frame: Month 24

  8. Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb3

    Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.

    Time frame: Baseline, Month 24

07

Results

Posted Jun 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneMigalastat HCl 150 mg
Started16
Completed15
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug

Number of subjects with TEAE, SAE, and AE leading to discontinuation during the study period

Time frame:
Entire study
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug
ParticipantsMigalastat HCl 150 mg
Number of subjects with TEAEs13
Number of subjects with SAE1
Number of subjects with AE leading to discontinuation0
SecondaryChange From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)

Estimated GFR was calculated using the modified Schwartz formula according to the standards of the central laboratory.

Time frame:
Baseline, Month 24
Reported as:
Mean · mL/min x 1.73 m2
Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)
mL/min x 1.73 m2Migalastat HCl 150 mg
Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)-27.6 ± 8.88
SecondaryChange From Baseline to Month 24 in Urine Protein Levels

Renal function was assessed by urine protein levels (mg/L). Urine samples were collected as part of urinalysis.

Time frame:
Baseline, Month 24
Reported as:
Mean · mg/L
Change From Baseline to Month 24 in Urine Protein Levels
mg/LMigalastat HCl 150 mg
Change From Baseline to Month 24 in Urine Protein Levels38.6 ± 79.03
SecondaryChange From Baseline to Month 24 in Urine Albumin

Renal function was assessed by urine albumin levels (mg/L). Urine samples were collected as part of urinalysis

Time frame:
Baseline, Month 24
Reported as:
Mean · mg/L
Change From Baseline to Month 24 in Urine Albumin
mg/LMigalastat HCl 150 mg
Change From Baseline to Month 24 in Urine Albumin-12.7 ± 21.73
SecondaryChange From Baseline to Month 24 in Left Ventricular Mass Index (LVMi)

LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M-mode and 2D views are presented.

Time frame:
Baseline, Month 24
Reported as:
Mean · g/m2
Change From Baseline to Month 24 in Left Ventricular Mass Index (LVMi)
g/m2Migalastat HCl 150 mg
2D-mode View4.75 ± 16.679
M-mode View6.01 ± 9.014
SecondaryChange From Baseline to Month 24 in Pediatric and Quality of Life Inventory™ (PedsQL™) Scores

The Pediatric Quality of Life Inventory (PedsQL™) was a modular approach to measuring health-related quality of life (QoL) in healthy children and adolescents and those with acute and chronic health conditions. All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Psychosocial, physical, and total scores were calculated based on the response to the questions within the patient reported outcome. The psychosocial score for the PedsQL encompassed 15 questions relating to the subjects' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the subjects' ease of managing physical activity. Total scores were the sum of all the item scores over the number of items answered on all the scales. Change from baseline values of \<0 represents worsening, 0 equals no change, and \>0 represents improvement.

Time frame:
Baseline, Month 24
Reported as:
Median · score on a scale
Change From Baseline to Month 24 in Pediatric and Quality of Life Inventory™ (PedsQL™) Scores
score on a scaleMigalastat HCl 150 mg
Psychosocial Score0 (-10 to 28)
Physical Score0 (-19 to 19)
Total Score-1.1 (-9 to 25)
SecondaryChange From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity

The Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) included questions about Fabry disease-specific symptoms. The assessment of "How bad is your pain today?" was measured on a 10- point scale from 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.

Time frame:
Baseline, Month 24
Reported as:
Mean · score on a scale
Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity
score on a scaleMigalastat HCl 150 mg
Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity-1.3 ± 3.20
SecondaryNumber of Subjects Who Experienced Sudden Onset of Pain As Assessed Using the Fabry-Specific Health and Pain Questionnaire (FPHPQ)

Subjects were asked "In the last 3 months how many times did you experience sudden onset of pain?" and responses were reported in the FPHPQ. Responses were categorized as 0, 1 to 3, 4 to 6, and \> 6 occurrences of sudden onset of pain.

Time frame:
Month 24
Reported as:
Count of participants · Participants
Number of Subjects Who Experienced Sudden Onset of Pain As Assessed Using the Fabry-Specific Health and Pain Questionnaire (FPHPQ)
ParticipantsMigalastat HCl 150 mg
No occurrences3
1 to 3 occurrences4
4 to 6 occurrences0
>6 occurrences1
SecondaryChange From Baseline to Month 24 in Plasma Levels of Lyso-Gb3

Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.

Time frame:
Baseline, Month 24
Reported as:
Mean · ng/mL
Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb3
ng/mLMigalastat HCl 150 mg
Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb30.05 ± 1.127

Adverse events

Collected over Adverse event data collected over duration of the study. Duration of participation varied by patient (range: 181 to 1457 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat HCl 150 mg0/16 (0%)1/16 (6.3%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
EventMigalastat HCl 150 mg
GastroenteritisInfections and infestations1/16
Most frequent other events
Showing 10 of 52
Most frequent other events
EventMigalastat HCl 150 mg
Covid-19Infections and infestations3/16
NasopharyngitisInfections and infestations3/16
Aspartate aminotransferase increasedInvestigations3/16
DizzinessNervous system disorders3/16
CoughRespiratory, thoracic and mediastinal disorders2/16
Blood bilirubin increasedInvestigations2/16
ParaesthesiaNervous system disorders2/16
DiarrhoeaGastrointestinal disorders2/16
Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
Raynaud's phenomenonVascular disorders1/16

Baseline characteristics

Age, Customized
Age, Customized(Participants)Migalastat HCl 150 mg
12 to < 16 years7
16 to < 18 years9
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat HCl 150 mg
Female6
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Migalastat HCl 150 mg
Hispanic or Latino1
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Migalastat HCl 150 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race1
Unknown or Not Reported0
Prior Enzyme Replacement Therapy (ERT) status
Prior Enzyme Replacement Therapy (ERT) status(Participants)Migalastat HCl 150 mg
ERT-experienced8
ERT-naive8
08

Study locations

6 sites
  • University of South Florida
    Tampa, Florida 33606, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • University of Minnesota Masonic Children's Hospital and Clinics
    Minneapolis, Minnesota 55454, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Lysosomal & Rare Disorders Research & Treatment Center
    Fairfax, Virginia 22030, United States
  • Royal Free London NHS Foundation Trust
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Nov 2024, 61 months.

Results were first posted in Jun 2025, 6 months after primary completion.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 8, 2019
StartActual
Oct 11, 2019
Primary completionActual
Nov 29, 2024
CompletionActual
Nov 29, 2024
Results first posted
Jun 17, 2025
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04049760
Responsible party
Sponsor
First posted
Aug 8, 2019
Start date
Oct 11, 2019
Primary completion
Nov 29, 2024
Completion
Nov 29, 2024
Results posted
Jun 17, 2025
Last update
Feb 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion